Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Clin Endocrinol Diabetes ; 115(3): 192-7, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17427110

RESUMEN

Among specific diabetes subtypes secondary to pancreatopathies, hereditary hemochromatosis is an inherited disorder of iron metabolism resulting in excessive iron overload and tissue damage in various organs. We here report the case of a man with the young-onset form of the disease and describe his glycaemic status before and during venesection therapy. A 25-year old man visited our clinic in Athens, Greece, with hypogonadotropic hypogonadism due to hereditary hemochromatosis. Genetic analysis revealed that he was suffering from the juvenile aggressive form and treatment was initiated with frequent phlebotomies in conjunction with androgen substitution. Within 18 months of therapy ferritin level was normalized and hypogonadism was fully restored. Despite severe iron overload, glucose tolerance remained normal during the various stages of the disease, although alterations in both insulin secretion and sensitivity were detected. Present data indicate that in juvenile hemochromatosis, the efficacy of the chelation therapy and probably the chronic interval required to restore normal iron concentration both play important roles in the formation of glucose metabolism characteristics.


Asunto(s)
Glucemia/metabolismo , Hemocromatosis/sangre , Hemocromatosis/complicaciones , Insulina/metabolismo , Adulto , Prueba de Tolerancia a la Glucosa , Hemocromatosis/genética , Humanos , Insulina/sangre , Secreción de Insulina , Masculino
2.
Exp Clin Endocrinol Diabetes ; 115(1): 50-4, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17286236

RESUMEN

Herein we describe the case of a 64-year-old woman with hypoparathyroidism diagnosed at the age of 40, after an acute episode of tetany and seizures due to severe hypocalcemia. She was treated for more than 20 years with calcitriol and calcium supplementation but she presented with marked hypercalciuria and recently nephrolithiasis, although serum calcium was maintained at levels below normal range. Provided that any attempt to increase the recommended dose of calcitriol was leading to an exacerbation of hypercalciuria, we decided to enroll an alternative tool in the treatment strategy. In order to avoid further deterioration of renal function she was administered once-daily a subcutaneous (sc) injection of synthetic human parathyroid hormone (PTH 1-34) while doses of calcium and calcitriol were gradually decreased depending on the response of calcium metabolism in serum and urine samples taken periodically. Within two months of administration, PTH (1-34) significantly reduced the level of urine calcium excretion compared with calcitriol therapy and maintained serum calcium in the normal range. The relevant literature is reviewed in light of this alternative therapeutic approach in long-standing hypoparathyroidism, illustrating the potential benefits and the unresolved issues in parathyroid hormone replacement.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Terapia de Reemplazo de Hormonas , Hipoparatiroidismo/tratamiento farmacológico , Teriparatido/uso terapéutico , Adulto , Calcitriol/administración & dosificación , Calcio/sangre , Calcio/orina , Femenino , Humanos , Hipoparatiroidismo/sangre , Hipoparatiroidismo/orina , Inyecciones Subcutáneas , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA